Literature DB >> 23694857

Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity.

Hans Strid1, Magnus Simrén, Anders Lasson, Stefan Isaksson, Mats Stridsberg, Lena Öhman.   

Abstract

BACKGROUND: Little is known of the importance of chromogranins (Cg) and secretogranins (Sg) in ulcerative colitis (UC). We therefore investigated fecal levels of CgA, CgB, SgII and SgIII, and their association with inflammatory activity, disease duration and medical therapy in UC.
METHODS: Analyses of CgA, CgB, SgII, SgIII and calprotectin in stool samples from 41 UC patients and 29 healthy controls were performed. Two stool samples, during relapse and remission, respectively, were obtained from each UC patient.
RESULTS: The levels of fecal CgA and SgII were higher in UC patients with active disease as compared to healthy controls. CgB and SgII were positively correlated with disease duration, but none of the granins were positively correlated with calprotectin, Mayo score, CRP or serum concentrations of TNF in UC patients with active disease. Also UC patients in remission had higher levels of CgA, CgB, SgII, and SgIII as compared to healthy controls. However, levels of fecal CgA, CgB, SgII and SgIII were lower during active disease relative to remission. Moreover, fecal levels of CgA and SgII were higher in UC patients in remission treated with thiopurines than in thiopurine-naïve patients in remission.
CONCLUSION: Fecal chromogranins and secretogranins are increased in UC but are not associated with disease activity, but seem to increase with duration of the disease. Thus, fecal granins might reflect structural changes associated with chronicity of disease, or medical therapy.
Copyright © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chromogranin; IBD; Secretogranin; Ulcerative colitis

Mesh:

Substances:

Year:  2013        PMID: 23694857     DOI: 10.1016/j.crohns.2013.04.019

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  8 in total

Review 1.  Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity.

Authors:  J J Worthington; F Reimann; F M Gribble
Journal:  Mucosal Immunol       Date:  2017-08-30       Impact factor: 7.313

Review 2.  A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.

Authors:  Stacy B Menees; Corey Powell; Jacob Kurlander; Akash Goel; William D Chey
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

3.  Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic Perspective.

Authors:  Valerie C Wasinger; Yunki Yau; Xizi Duo; Ming Zeng; Beth Campbell; Sean Shin; Raphael Luber; Diane Redmond; Rupert W L Leong
Journal:  Mol Cell Proteomics       Date:  2015-11-03       Impact factor: 5.911

4.  Evidence of increased fecal granins in children with irritable bowel syndrome and correlates with symptoms.

Authors:  Robert J Shulman; Lena Öhman; Mats Stridsberg; Kevin Cain; Magnus Simrén; Margaret Heitkemper
Journal:  Neurogastroenterol Motil       Date:  2018-10-09       Impact factor: 3.598

Review 5.  Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.

Authors:  Magdy El-Salhy; Tefera Solomon; Trygve Hausken; Odd Helge Gilja; Jan Gunnar Hatlebakk
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

6.  Digital Spatial Profiling Reveals Functional Shift of Enterochromaffin Cell in Patients With Ulcerative Colitis.

Authors:  Dongping Lyu; Guanjun Kou; Shiyang Li; Lixiang Li; Bing Li; Ruchen Zhou; Xiaoxiao Yang; Wenyu Tian; Yanqing Li; Xiuli Zuo
Journal:  Front Cell Dev Biol       Date:  2022-04-08

Review 7.  A Novel Pathway of Flavonoids Protecting against Inflammatory Bowel Disease: Modulating Enteroendocrine System.

Authors:  Mingrui Li; Benno Weigmann
Journal:  Metabolites       Date:  2022-01-01

8.  A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.

Authors:  R Gacesa; A Vich Vila; V Collij; Z Mujagic; A Kurilshikov; M D Voskuil; E A M Festen; C Wijmenga; D M A E Jonkers; G Dijkstra; J Fu; A Zhernakova; F Imhann; R K Weersma
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.